PRINCETON, NJ – Certara®, the global model-informed drug development and decision support leader, today announced the launch of BaseCase Data Manager, which allows clients to build interactive, data-driven mobile tools using real-world data sources, such as healthcare claims, costs, quality, outcomes, and population data. BaseCase Data Manager is able to handle such large datasets because it […]
A panel discussion with industry leaders on the future of microbiome R&D headlined our celebratory launch event in New York City. New York City (US) – We are excited to announce that our new office at JLABS in Manhattan, New York City, opened its doors on Thursday, July 25. As part of the New York Genome […]
PRINCETON, NJ – Certara®, the global model-informed drug development and decision support leader, today announced the launch of version 19.6 of D360, its scientific informatics platform for drug discovery and development. Designed to meet the scientific researcher’s need to quickly access, understand and share data, the D360 platform is delivered through its toolkits – small […]
OncoImmunity AS today announced that it has been acquired by NEC Corporation, the renowned Japanese IT and network company, that recently launched its Artificial Intelligence (AI) driven drug discovery business. OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS. OncoImmunity AS, founded in 2014, develops software that […]
San Mateo, CA, United States – BlueBee is pleased to announce the expansion of its senior management team with the appointment of Pam Cheng, Ph.D., as Vice President of Product Management and Strategy. Pam joins BlueBee with expertise in clinical bioinformatics honed from her years of experience at Illumina, Complete Genomics, and Agilent Technologies. As a […]
Cambridge, United Kingdom – 22 July 2019 – Congenica, a digital health company enabling accelerated genomic data interpretation, today announced it has renamed its software platform Congenica® and expanded its capabilities to include CNV calling for exome and gene panel sequencing. The latest software version will continue to streamline and enhance genomic clinical interpretation and help to reduce […]
Paris Atos, a global leader in digital transformation, was selected by GCS AURAGEN[1] – to provide and orchestrate the high-performance computing infrastructure and storage of a new genomic pilot platform for high-flow sequencing calculation. This platform has been selected as part of the French national plan for Genomic Science (‘France Médecine Génomique 2025’[2]). Atos will manage […]
PRINCETON, NJ – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire staff from Compass Strategic Consulting (Compass) has joined Certara’s Evidence & Access group. Certara Evidence & Access was formed through the acquisition of Analytica Laser (market access, health economics and real-world […]
PRINCETON, NJ – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide. CGH is a new product […]
Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies Basel, Switzerland ‒ Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced that Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer, […]
Pay Invoice
Latest Blogs
-
MOBILion Expands into Proteomics MS Market
April 30, 2026 5:05 pm
-
Carterra Introduces Faster SPR
March 27, 2026 7:26 pm
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
